We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TYME

News List

Tyme’s Oncology Research Identifies Potential New Oral Therapy TYME-19 for COVID-19 americanpharmaceuticalreview
August 28, 2020
Tyme Technologies announced a potential new approach to treating COVID-19 using a metabolic agent, TYME-19.
TYME Announces First Patient Dosed in Metastatic Pancreatic Cancer Treatment Trial americanpharmaceuticalreview
January 13, 2020
Tyme Technologies announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer.
Tyme and Eagle Pharmaceuticals partner for cancer candidate oral pharmaceutical-technology
January 09, 2020
Tyme Technologies has entered a strategic collaboration with Eagle Pharmaceuticals for cancer metabolism-based therapy (CMBT) candidate oral SM-88.
TYME Technologies, NYU Langone to Advance Metastatic Cancer Treatment contractpharma
July 31, 2019
Aims to examine TYME’s metabolism-based cancer treatment, SM-88.